VivoSim Labs (FRA:4OR) Ending Cash Position: €3.78 Mil (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
38 GF Score
Price €3.49
GF Value €9.41
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Ending Cash Position?

VivoSim Labs FRA:4OR 38 Ending Cash Position is €3.78 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €9.41. The stock has 4 warning signs investors should review.

VivoSim Labs's Ending Cash Position for the quarter that ended in Dec. 2025 was €3.78 Mil.

VivoSim Labs's quarterly Ending Cash Position declined from Jun. 2025 (€7.98 Mil) to Sep. 2025 (€5.81 Mil) and declined from Sep. 2025 (€5.81 Mil) to Dec. 2025 (€3.78 Mil).

VivoSim Labs's annual Ending Cash Position declined from Mar. 2023 (€14.43 Mil) to Mar. 2024 (€2.80 Mil) but then increased from Mar. 2024 (€2.80 Mil) to Mar. 2025 (€10.60 Mil).

VivoSim Labs Ending Cash Position Related Terms

VivoSim Labs Ending Cash Position Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Ending Cash Position Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.48 26.17 14.43 2.80 10.60

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 10.60 7.98 5.81 3.78
FRA:4OR
38GF Score
VivoSim Labs Inc FRA:4OR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

VivoSim Labs's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.816+7.78
=10.60

VivoSim Labs's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.824+-2.04
=3.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €3.78 Mil mean?
VivoSim Labs (FRA:4OR) has a Ending Cash Position of €3.78 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Ending Cash Position too high?
VivoSim Labs' current Ending Cash Position is €3.78 Mil. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Ending Cash Position compare to SLXN and CDT?
VivoSim Labs' Ending Cash Position of €3.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Ending Cash Position is €3.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Ending Cash Position of €3.78 Mil. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current Ending Cash Position is €3.78 Mil. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Ending Cash Position is €3.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.

Key valuation signals for FRA:4OR:

  • Ending Cash Position: €3.78 Mil
  • GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score

Get the complete analysis for FRA:4OR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€9.41
GF Value